View Post

KAMILLA Data Reinforce Favorable Benefit/Risk Profile of T-DM1 in HER2+ Breast Cancer

In Clinical Studies News by Barbara Jacoby

By: Ryan Scott From: onclive.com Rachel Wuerstlein, MD, discusses the safety and the efficacy observed with ado-trastuzumab emtansine in patients with HER2-positive breast cancer and the next steps for research with the agent. Data from the phase 3 KAMILLA trial (NCT01702571) confirm the safety and efficacy of ado-trastuzumab emtansine (T-DM1, Kadcyla) that had previously been observed in patients with previously …

View Post

Virtual intervention reduces fear of breast cancer recurrence

In Clinical Studies News by Barbara Jacoby

By: Will Doss, Northwestern University From: medicalxpress.com A targeted virtual health intervention was effective for reducing fear of recurrence among breast cancer survivors, according to a clinical trial published in the Journal of the National Cancer Institute. Fear of recurrence can cause anxiety and related symptoms, so implementing effective and convenient strategies can improve quality of life for survivors of …

View Post

G1 Therapeutics Receives Fast Track Designation from U.S. Food and Drug Administration for COSELA™ (Trilaciclib) in Combination with Chemotherapy for the Treatment of Locally Advanced or Metastatic Triple Negative Breast Cancer

In Clinical Studies News by Barbara Jacoby

Source: G1 Therapeutics From: finance.yahoo.com G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to COSELA™ (trilaciclib) investigation for use in combination with chemotherapy for the treatment of locally advanced or metastatic triple negative breast cancer (TNBC). COSELA is currently being evaluated in PRESERVE 2, …

View Post

Talazoparib Is Active in gBRCA1/2 Mutation-Positive, HER2-Negative Early Breast Cancer

In Clinical Studies News by Barbara Jacoby

By: Walter Alexander From: cancertherapyadvisor.com Neoadjuvant talazoparib demonstrated activity and pathologic complete response (pCR) rates comparable to those observed with combination anthracycline and taxane-based chemotherapy regimens in a phase 2 trial of patients with germline BRCA1/2 (gBRCA1/2) mutation-positive, HER2-negative early breast cancer. The results were presented by Jennifer Keating Litton, MD, of The University of Texas MD Anderson Cancer Center …

View Post

CytoDyn’s Trial for Metastatic Triple-Negative Breast Cancer Demonstrates Safety with 350 mg, 525 mg and 700 mg Dosages; Officially Advances to Phase 2 from Phase 1b

In Clinical Studies News by Barbara Jacoby

Source: CytoDyn From: biospace.com CytoDyn Inc. (OTCQB: CYDY) (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced today its clinical trial with leronlimab in combination with carboplatin for the treatment of metastatic triple-negative breast cancer (mTNBC) has advanced from Phase 1b to a Phase 2 trial. The positive …

View Post

Updated recommendations for managing hereditary breast cancer

In Clinical Studies News by Barbara Jacoby

Source: Health Day From: medicalxpress.com One year of adjuvant olaparib should be offered to patients with high-risk early-stage human epidermal growth factor receptor 2 (HER2)-negative breast cancer and germline BRCA mutations after completion of (neo)adjuvant chemotherapy and local treatment, according to a rapid recommendation update published by the American Society for Clinical Oncology (ASCO). Following presentation of the results from …

View Post

Savvy Cooperative: Patients who were Part of a Clinical Trial During the COVID-19 Pandemic

In Paid Opportunities For The Cancer Community by Barbara Jacoby

Scope: We need patients who were part of a clinical trial during the COVID-19 pandemic Eligibility Criteria: Were part of a clinical trial during covid Proof of diagnosis/participation will be required to participate Geography: USA Details: Video interview with Savvy that Savvy will edit down into a highlight reel to be used in a pharmaceutical company’s internal meeting as well …

View Post

Positive Topline Survival Data Observed in Phase 3 Trial of SYD985 for HER2-Positive Metastatic Breast Cancer

In Clinical Studies News by Barbara Jacoby

By: Matthew Fowler From: cancernetwork.com Data from the phase 3 TULIP trial showed that [vic-]trastuzumab duocarmazine yielded positive progression-free survival for patients with pretreated HER2-positive metastatic breast cancer. Positive topline results were observed in the phase 3 TULIP study (NCT03262935), which investigated the safety and efficacy of [vic-]trastuzumab duocarmazine (SYD985) compared with physician’s choice of chemotherapy in patients with pretreated …

View Post

FDA Approves Dose-Escalation Label Update for Neratinib in HER2+ Breast Cancer

In Clinical Studies News by Barbara Jacoby

By: Kristi Rosa From: onclive.com THe FDA has approved a labeling supplement to the US prescribing information for neratinib that includes the dose-escalated use of the agent in patients with HER2-positive breast cancer, as examined in the phase 2 CONTROL trial, and the new 133-count commercial Nerlynx SKU. The FDA has approved a labeling supplement to the US prescribing information …

View Post

City of Hope researchers ID how most common breast cancer becomes resistant to treatment

In Clinical Studies News by Barbara Jacoby

Source: City of Hope From: eurekalert.org Understanding how tumors in patients with early-stage estrogen receptor positive breast cancer evolve to resist certain combination therapies can aid in the design of optimal drug strategies for people whose cancer potentially could be cured City of Hope, a world-renowned cancer research and treatment center, has identified how cancer cells in patients with early-stage …